ArticleWorld journal of hepatology2014
Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease.
Article in World journal of hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.
- Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.Alimentary pharmacology & therapeutics · 2020Guideline
- Vorasidenib-Induced Acute Liver Injury.Digestive diseases and sciences · 2026Article
- Sexual dimorphism in the liver.Nature reviews. Gastroenterology & hepatology · 2026Review
- Human Leukocyte Antigen (International journal of molecular sciences · 2026Review
- From Therapy to Toxicity: A Rare Case of Acute Piperacillin/Tazobactam-Associated Drug-Induced Liver Injury.Cureus · 2025Article
- Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms.Diagnostics (Basel, Switzerland) · 2025Review
- Autoimmune Hepatitis (AIH) Related to Drug-Induced Liver Injury (DILI) Due to Atorvastatin.Cureus · 2025Article
- Clinicopathological characteristics of autoimmune‑like hepatitis after drug‑induced liver injury.Biomedical reports · 2025Article
- Are Gender Differences Important for Autoimmune Liver Diseases?Life (Basel, Switzerland) · 2024Review
- Denosumab-induced autoimmune hepatitis: Case report.Clinical case reports · 2024Article
- Article
- A Rare Presentation of Drug-Induced Autoimmune Hepatitis and the Role of Male Enhancement Supplements.Cureus · 2024Article
- Comparison of the recommendation of international autoimmune hepatitis pathology group 2022 and the simplified criteria for autoimmune hepatitis 2008: A preliminary study.Hepatology forum · 2024Article
- Drug induced autoimmune hepatitis: An unfortunate case of herbal toxicity from Skullcap supplement: A case report.World journal of hepatology · 2023Article
- Drug-induced liver injury with autoimmune features secondary to infliximab for ulcerative colitis.BMJ case reports · 2023Article
- Investigating Acute Hepatitis after SARS-CoV-2 Vaccination or Infection: A Genetic Case Series.Biomedicines · 2023Article
- Article
- Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.Journal of hepatology · 2023Review
- A diagnostic challenge: Life-threatening drug reaction with eosinophilia and systemic symptoms in the setting of a SARS-CoV-2 and human herpesvirus-6 reactivation in a patient with severe hepatic injury on bupropion.JAAD case reports · 2023Article
- Characteristics and Long-Term Outcome of 535 Patients with Autoimmune Hepatitis-The 20-Year Experience of a High-Volume Tertiary Center.Journal of clinical medicine · 2023Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aetiology of autoimmune hepatitis (AIH) is uncertain but the disease can be triggered in susceptible patients by external factors such as viruses or drugs. AIH usually develops in individuals with a genetic background mainly consisting of some risk alleles of the major histocompatibility complex (HLA). Many drugs have been linked to AIH phenotypes, which sometimes persist after drug discontinuation, suggesting that they awaken latent autoimmunity. At least three clinical scenarios have been proposed that refers to drug- induced autoimmune liver disease (DIAILD): AIH with drug-induced liver injury (DILI); drug induced-AIH (DI-AIH); and immune mediated DILI (IM-DILI). In addition, there are instances showing mixed features of DI-AIH and IM-DILI, as well as DILI cases with positive autoantibodies. Histologically distinguishing DILI from AIH remains a challenge. Even more challenging is the differentiation of AIH from DI-AIH mainly relying in histological features; however, a detailed standardised histologic evaluation of large cohorts of AIH and DI-AIH patients would probably render more subtle features that could be of help in the differential diagnosis between both entities. Growing information on the relationship of drugs and AIH is being available, being drugs like statins and biologic agents more frequently involved in cases of DIAILD. In addition, there is some evidence on the fact that patients diagnosed with DIAILD may have had a previous episode of hepatotoxicity. Further collaborative studies in DIAILD will strengthen the knowledge and understanding of this intriguing and complex disorder which might represent different phenotypes across the spectrum of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.